首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >The value of clinical and laboratory diagnostics for chest pain patients at the emergency department
【24h】

The value of clinical and laboratory diagnostics for chest pain patients at the emergency department

机译:急诊科对胸痛患者的临床和实验室诊断价值

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: The focus during the diagnostic process for patients with acute chest pain is to discriminate patients who can be safely discharged from those who are at risk for an acute coronary syndrome (ACS). In this study the diagnostic value of the clinical examination is compared with laboratory testing of troponin., Methods: This study included 710 chest pain patients who presented at the ED of two hospitals in the Netherlands. Clinical examination and laboratory testing were combined in the recently developed HEART-score. The diagnostic values of clinical presentation, troponin and the HEART-score for a major adverse coronary event (MACE) and an ACS within 6 weeks were assessed. Furthermore, the improvement of HEART with the second troponin measurement after 6 h was assessed using the net reclassification improvement (NRI)., Results: The use of HEART (AUCMACE: 0.77; AUCACS: 0.82) obtains a higher diagnostic value than troponin (AUCMACE: 0.72; AUCACS: 0.74) or clinical evaluation (AUCMACE: 0.69; AUCACS: 0.74). Statistical significant different AUCs were obtained when HEART is compared to troponin or clinical evaluation (p < 0.01). The use of the second troponin test (after 6 h of admission) within HEART resulted in an improvement of 8.0%., Conclusions: The HEART-score combines clinical evaluation and results from laboratory testing, which should be used together, to discriminate patients at risk of a cardiac event from patients who can be safely discharged. In addition, it is shown that a second troponin measurement slightly improves the discriminative ability of the HEART-score.
机译:背景:在急性胸痛患者的诊断过程中,重点是将可以安全出院的患者与有急性冠脉综合征(ACS)风险的患者区分开。在这项研究中,将临​​床检查的诊断价值与肌钙蛋白的实验室检查进行了比较。方法:该研究包括710名在荷兰两家医院的急诊科就诊的胸痛患者。最近开发的HEART评分结合了临床检查和实验室测试。评估了临床表现,肌钙蛋白和HEART评分在6周内对主要不良冠脉事件(MACE)和ACS的诊断价值。此外,使用净重分类改善(NRI)评估了6小时后第二次肌钙蛋白测量对HEART的改善。结果:使用HEART(AUCMACE:0.77; AUCACS:0.82)比肌钙蛋白(AUCMACE)获得更高的诊断价值:0.72; AUCACS:0.74)或临床评估(AUCMACE:0.69; AUCACS:0.74)。当将HEART与肌钙蛋白比较或进行临床评估时,获得了统计学上显着不同的AUC(p <0.01)。在HEART内使用第二次肌钙蛋白测试(入院6小时后)改善了8.0%。结论:HEART评分结合了临床评估和实验室测试的结果,应结合使用以区分以下患者:可以安全出院的患者引起心脏病的风险。此外,还显示第二次肌钙蛋白的测量可以稍微改善HEART评分的判别能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号